1. Acute heart failure and adverse events associated with the presence of renal dysfunction and hyperkalaemia. EAHFE- renal dysfunction and hyperkalaemia
- Author
-
Jacob, J, Llauger, L, Herrero-Puente, P, Martin-Sanchez, FJ, Llorens, P, Gil, V, Fuentes, M, Miro, O, Gil, C, Alonso, H, Perez-Llantada, E, Llopis-Garcia, G, Santos-Matallana, MC, Barrenechea-Moxo, MLD, Salgado-Perez, L, Escoda, R, Xipell, C, Sanchez, C, Gaytan, JM, Perez-Dura, MJ, Salvo, E, Pavon, J, Noval, A, Torres, JM, Lopez-Grima, ML, Valero, A, Juan, MA, Aguirre, A, Pedragosa, MA, Minguez-Maso, S, Alonso, MI, Ruiz, F, Franco, JM, Mecina, AB, Tost, J, Berenguer, M, Donea, R, Sanchez-Ramon, S, Carbajosa-Rodriguez, V, Pinera, P, Sanchez-Nicolas, JA, Garate, RT, Alquezar-Arbe, A, Rizzi, MA, Herrera, S, Roset, A, Cabello, I, Haro, A, Richard, F, Alvarez-Perez, JM, Lopez-Diez, MP, Vazquez-Alvarez, J, Prieto-Garcia, B, Garcia, MG, Gonzalez, MS, Javaloyes, P, Marquina, V, Jimenez, I, Hernandez, N, Brouzet, B, Espinosa, B, Andueza, JA, Romero, R, Ruiz, M, Calvache, R, Serralta, MTL, Javez, LEC, Arriaga, BA, Bergua, BS, Mojarro, EM, Jimenez, BSA, Becquer, LT, Burillo, G, Garcia, LL, LaSalle, GC, Urbano, CA, Soto, ABG, Padial, ED, Ferrer, ES, Garrido, JM, Lucas-Imbernon, FJ, Gaya, R, Bibiano, C, Mir, M, Rodriguez, B, Carballo, JL, Rodriguez-Adrada, E, and Miranda, BR
- Subjects
Hyperkalaemia ,Acute heart failure ,Renal dysfunction ,Outcomes - Abstract
Objective: To study the outcomes of patients with acute heart failure (AHF) presenting renal dysfunction (RD) or hyperkalaemia (Hk) alone or in combination. Method: We analysed the data of the EAHFE registry, a multicentre, non interventionist cohort with prospective follow-up of patients with AHF. Four groups were defined based on the presence or not of RD or Hk alone or in combination. The primary endpoint was 30-day all-cause mortality. Results: A total of 11,935 of the 13,791 patients included in the EAHFE registry were analysed. Of these, 5088 (42.6%) did not have RD or Hk (NoRD-NoHk), 150 (1.3%) had no RD but had Hk (NoRD-Hk), 6012 (50.4%) had RD but not Hk (RD-NoHk) and 685 (5.7%) had both RD and Hk (RD-Hk). Thirty-day all-cause mortality was greatest in the RD-Hk group with an adjusted Hazard Ratio (HR) of 2.44 (confidence interval 95% [C195%] 1.67-3.55; p < 0.001) and in the RD-NoHk group with an adjusted HR of 1.34 (CI95% 1.04-1.71; p = 0.022). There were no significant differences in in-hospital mortality and reconsultation at 30 days for HF. For the combined endpoint of 30-day all-cause mortality the adjusted HR was 1.33 (CI95% 1.04-1.70); (p = 0.021) for the RD-Hk group. Conclusions: The association of 30-day all-cause mortality with the presence of RD and Hk in patients presenting AHF at admission is greater than in those without this combination.
- Published
- 2019